Related Experiment Video
Updated: Jan 8, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.7K
Colchicine for Major Adverse Cardiovascular Events: An Updated ChatGPT-Assisted Systematic Review and Meta-Analysis
Lefteris Teperikidis1,2,3, Aristi Boulmpou3, Manisha Chownk1
1Synthesa, Inc., New York, NY.
Journal of Cardiovascular Pharmacology
|December 17, 2025
Summary
Colchicine shows promise in reducing major adverse cardiovascular events (MACE) for heart disease prevention. However, its impact on specific events like heart attack and stroke requires further investigation.
Area of Science:
- Cardiology
- Pharmacology
- Artificial Intelligence in Medicine
Background:
- Colchicine, an anti-inflammatory drug, has been explored for cardiovascular prevention.
- Previous randomized trials on its efficacy have yielded inconsistent results.
Purpose of the Study:
- To evaluate the efficacy and safety of colchicine in reducing major adverse cardiovascular events (MACE) and its components.
- To assess the utility of ChatGPT as an AI assistant in conducting systematic reviews and meta-analyses.
Main Methods:
- Systematic identification and meta-analysis of 11 randomized trials involving 30,888 patients.
- Data extraction, risk of bias assessment, and statistical analysis were performed with ChatGPT assistance under human supervision.
Main Results:
- Colchicine significantly reduced the risk of MACE (risk ratio 0.75, 95% CI 0.63-0.88).
- No significant reductions were observed for myocardial infarction, stroke, cardiovascular mortality, or all-cause mortality.
- The use of ChatGPT reduced researcher time by over 70% with maintained accuracy.
Conclusions:
- Colchicine may lower the risk of MACE in cardiovascular prevention, although certainty is reduced by specific trial results.
- This study demonstrates the feasibility and efficiency of using large language models like ChatGPT in evidence synthesis.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
4.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.0K
01:21Rheumatic Heart Disease III: Medical Management
264
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
264
01:27Coronary Artery Disease V: Interprofessional Care
203
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
203
01:26Coronary Artery Disease IV: Preventive Measures
572
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
572
01:26Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
01:17Pericarditis III: Medical Management
281
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
281